Research Analysts Offer Predictions for PVLA FY2025 Earnings

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Stock analysts at Cantor Fitzgerald reduced their FY2025 earnings per share (EPS) estimates for shares of Palvella Therapeutics in a research report issued on Thursday, November 13th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings of ($3.40) per share for the year, down from their previous forecast of ($2.87). Cantor Fitzgerald currently has a “Overweight” rating and a $200.00 price target on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. Cantor Fitzgerald also issued estimates for Palvella Therapeutics’ FY2026 earnings at ($3.77) EPS.

PVLA has been the subject of a number of other reports. HC Wainwright upped their price objective on shares of Palvella Therapeutics from $95.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Wednesday, October 8th. Truist Financial upped their price target on shares of Palvella Therapeutics from $80.00 to $105.00 and gave the stock a “buy” rating in a research report on Monday, November 10th. Stifel Nicolaus lifted their price objective on Palvella Therapeutics from $60.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, September 24th. Finally, Chardan Capital reiterated a “buy” rating and set a $110.00 price objective on shares of Palvella Therapeutics in a research note on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $104.50.

Palvella Therapeutics Price Performance

Shares of NASDAQ:PVLA opened at $82.94 on Monday. The business’s 50 day moving average price is $69.86 and its 200-day moving average price is $45.77. Palvella Therapeutics has a 1 year low of $11.17 and a 1 year high of $87.01. The firm has a market capitalization of $981.68 million, a price-to-earnings ratio of -21.88 and a beta of -0.05.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings data on Tuesday, November 11th. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.18).

Institutional Trading of Palvella Therapeutics

Several large investors have recently bought and sold shares of PVLA. Archer Investment Corp acquired a new stake in Palvella Therapeutics in the 3rd quarter valued at about $28,000. Russell Investments Group Ltd. acquired a new stake in shares of Palvella Therapeutics in the third quarter valued at approximately $36,000. Police & Firemen s Retirement System of New Jersey purchased a new position in Palvella Therapeutics during the second quarter worth approximately $37,000. JPMorgan Chase & Co. boosted its stake in Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after buying an additional 3,242 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Palvella Therapeutics during the second quarter worth $85,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.